Our top pick for
Beginners
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
How to buy Titan Pharmaceuticals stock | 0.14
Own Titan Pharmaceuticals stock in just a few minutes.
Titan Pharmaceuticals, Inc is a biotechnology business based in the US. Titan Pharmaceuticals shares (TTNP) are listed on the NASDAQ and all prices are listed in US Dollars. Titan Pharmaceuticals employs 21 staff and has a trailing 12-month revenue of around USD$4.8 million.
How to buy shares in Titan Pharmaceuticals
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for Titan Pharmaceuticals Find the stock by name or ticker symbol: TTNP. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Titan Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of USD$0.14, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Titan Pharmaceuticals, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Titan Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
How has coronavirus impacted Titan Pharmaceuticals's share price?
Since the stock market crash in March caused by coronavirus, Titan Pharmaceuticals's share price has had significant negative movement.
Its last market close was USD$0.14, which is 41.18% down on its pre-crash value of USD$0.238 and 32.36% down on the lowest point reached during the March crash when the shares fell as low as USD$0.1853.
If you had bought USD$1,000 worth of Titan Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$967.78 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$585.77.
Titan Pharmaceuticals share price
Use our graph to track the performance of TTNP stocks over time.Titan Pharmaceuticals shares at a glance
Information last updated 2020-10-13.
| Latest market close | USD$0.14 |
|---|---|
| 52-week range | USD$0.142 - USD$0.4449 |
| 50-day moving average | USD$0.1923 |
| 200-day moving average | USD$0.2653 |
| Wall St. target price | USD$0.8 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-0.928 |
Compare trading platforms
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Titan Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Titan Pharmaceuticals price performance over time
Historical closes compared with the close of $0.14 from 2020-10-16
| 1 week (2020-10-13) | -12.50% |
|---|---|
| 1 month (2020-09-18) | -33.14% |
| 3 months (2020-07-20) | -55.23% |
| 6 months (2020-04-20) | -41.05% |
| 1 year (2019-10-18) | -19.91% |
|---|---|
| 2 years (2018-10-19) | -63.00% |
| 3 years (2017-10-20) | -92.63% |
| 5 years (2015-10-20) | -96.77% |
Titan Pharmaceuticals financials
| Revenue TTM | USD$4.8 million |
|---|---|
| Gross profit TTM | USD$-4,919,000 |
| Return on assets TTM | -123.22% |
| Return on equity TTM | -3431.55% |
| Profit margin | 0% |
| Book value | $0.016 |
| Market capitalisation | USD$18 million |
TTM: trailing 12 months
Shorting Titan Pharmaceuticals shares
There are currently 6.4 million Titan Pharmaceuticals shares held short by investors – that's known as Titan Pharmaceuticals's "short interest". This figure is 5% down from 6.8 million last month.
There are a few different ways that this level of interest in shorting Titan Pharmaceuticals shares can be evaluated.
Titan Pharmaceuticals's "short interest ratio" (SIR)
Titan Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Titan Pharmaceuticals shares currently shorted divided by the average quantity of Titan Pharmaceuticals shares traded daily (recently around 3.9 million). Titan Pharmaceuticals's SIR currently stands at 1.65. In other words for every 100,000 Titan Pharmaceuticals shares traded daily on the market, roughly 1650 shares are currently held short.
However Titan Pharmaceuticals's short interest can also be evaluated against the total number of Titan Pharmaceuticals shares, or, against the total number of tradable Titan Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Titan Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Titan Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0551% of the tradable shares (for every 100,000 tradable Titan Pharmaceuticals shares, roughly 55 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Titan Pharmaceuticals.
Find out more about how you can short Titan Pharmaceuticals stock.
Titan Pharmaceuticals share dividends
We're not expecting Titan Pharmaceuticals to pay a dividend over the next 12 months.
Have Titan Pharmaceuticals's shares ever split?
Titan Pharmaceuticals's shares were split on a 1:6 basis on 25 January 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Titan Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Titan Pharmaceuticals shares which in turn could have impacted Titan Pharmaceuticals's share price.
Titan Pharmaceuticals share price volatility
Over the last 12 months, Titan Pharmaceuticals's shares have ranged in value from as little as $0.142 up to $0.4449. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Titan Pharmaceuticals's is 0.9068. This would suggest that Titan Pharmaceuticals's shares are less volatile than average (for this exchange).
Titan Pharmaceuticals overview
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction in patients. It also develops ProNeura-Ropinirole, an implant to provide delivery of ropinirole, a dopamine agonist for the treatment of Parkinson's disease; and triiodothyronine, an implant for the treatment of hypothyroidism. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.
Frequently asked questions
Ask an Expert